&lt;p&gt;Study on the Risk Factors for Hyperuricaemia and Related Vascular Complications in Patients with Type 2 Diabetes Mellitus&lt;/p&gt;

Shi, Rong; Niu, Zheyun; Wu, Birong; Hu, Fan

doi:10.2147/rmhp.s255042

Cited by 9 publications

(8 citation statements)

References 63 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the NF-κB pathway, which can increase the expression of ET-1, was inhibited by ET-1/ETBR, and the expression of ET-1 was significantly increased in ETBR gene knockout DN mice. 31,32 In this study, the ET-1 index of DN patients was significantly increased with the aggravation of proteinuria. This trend is in agreement with the above studies, indicating that ET-1 can reflect the severity of renal damage.…”

Section: Discussionsupporting

confidence: 53%

“…In patients with long term hyperglycemia, the renal micro vascular perfusion is poor, tissues become ischemic and hypoxic, and vascular endothelial cells are damaged. 32,33 These processes lead to abnormal micro vascular proliferation, abnormal proliferation of mesangial cells and massive extracellular matrix deposition in the mesangial area, resulting in glomerular sclerosis eventually. 34,35 As described in the above studies, VEGF and ET-1 play an important role in microangiogenesis and abnormal proliferation in the mesangial area, determining the extent of renal damage.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Clinical significance of vascular endothelial growth factor and endothelin-1 in serum levels as novel indicators for predicting the progression of diabetic nephropathy

Chu

et al. 2023

Eur J Inflamm

View full text Add to dashboard Cite

Objective: Early diagnosis and intervention of diabetic nephropathy (DN) is necessary to optimize therapy in order to delay the progression of diabetes. This research aimed to reveal the change of vascular endothelial growth factor (VEGF) and endothelin-1 (ET-1) in patients with DN, and to assess possible correlations with glycated hemoglobin (HbAlc) values. Methods: The present study was a retrospective, single-center study conducted at a teaching hospital in the northeast China. A total of 120 patients were divided into proteinuria-positive group ( n = 40), the microalbuminuria group ( n = 40), and the high proteinuria group ( n = 40) according to the urinary albumin excretion rate (UAER), and 40 healthy volunteers were selected as the control group. The levels of VEGF, ET-1 and HbA1c were measured in all subjects and principal component analysis (PCA) was performed to classify and reveal correlations between VEGF, ET-1 and HbA1c. Results: Compared to the control group, a significant difference in the increase of HbA1c was detected in group I, II and III. A significant increase in the concentrations of serum VEGF and ET-1 was also observed. HbA1c in DN patients had proven to be positively correlated with VEGF (r = 0.7941; p < 0. 0001) and ET-1 (r = 0.8504; p < 0.0001) respectively. Conclusion: The elevated levels of VEGF and ET-1 in serum have been proposed as being able to supplement the additional information about the progression of DN. These data suggest that the decrease in endothelial function may be related to poor glycemic control.

show abstract

Section: Discussionsupporting

confidence: 53%

Section: Discussionmentioning

confidence: 99%

Clinical significance of vascular endothelial growth factor and endothelin-1 in serum levels as novel indicators for predicting the progression of diabetic nephropathy

Chu

et al. 2023

Eur J Inflamm

View full text Add to dashboard Cite

show abstract

“…SUA is a strong independent, novel risk factor for diabetes [ 5 ]. Increases in body weight, waist circumference, dyslipidemia, sedentary lifestyle, hypertension, and insulin resistance are predisposing factors for hyperuricemia in patients with diabetes [ 6 , 7 ].…”

Section: Introductionmentioning

confidence: 99%

Sodium-Glucose Cotransporter-2 (SGLT-2) Attenuates Serum Uric Acid (SUA) Level in Patients with Type 2 Diabetes

Hussain

Elahi

Hussain

et al. 2021

Journal of Diabetes Research

View full text Add to dashboard Cite

Background. Hyperuricemia has a strong association with diabetes mellitus. Hyperuricemia can lead to cardiovascular and renal complications in patients with diabetes. The goal of this study was to compare the effect of sodium-glucose cotransporter-2 (SGLT-2) inhibitors dapagliflozin and empagliflozin on serum uric acid (SUA) levels in patients with type 2 diabetes against traditional oral antihyperglycemic drugs (OADs). Methods. In this double-blind randomized controlled trial, 70 patients with type 2 diabetes and elevated SUA levels were assigned to two treatment groups. Patients in group A received SGLT-2 inhibitors tablet dapagliflozin 5 mg to 10 mg and empagliflozin 10 mg to 25 mg. Group B patients received OADs such as glimepiride, metformin, sitagliptin, gliclazide, and glibenclamide as monotherapy or combination therapy. The changes in SUA level were primary end points while changes in body weight and body mass index (BMI) from baseline to end point were secondary end points. Results. After four weeks of treatment, we noted a significant reduction of mean SUA levels in the SGLT-2 inhibitor group from 7.5 ± 2.5 to 6.3 ± 0.8 mg/dl versus comparator group from 7.1 ± 1.8 to 6.8 ± 2.2 mg/dl ( p = 0.001 ). Mean body weight was significantly reduced in the SGLT-2 group from 82 ± 10.4 to 78 ± 12.5 kg versus comparator group from 78 ± 13.2 to 79.2 ± 9.7 kg ( p = 0.001 ). Similarly, the mean BMI of patients in the SGLT-2 group was significantly reduced from 25.7 ± 3.2 to 24.2 ± 3.2 kg/m2 versus comparator group from 27.5 ± 4.2 to 28 ± 3.6 kg/m2 ( p = 0.002 ). Conclusion. SGLT-2 inhibitors have a strong potential to decrease SUA levels in patients with type 2 diabetes.

show abstract

“…The incidence rate of HUA due to changes in population, lifestyle, dietary habits and drug use, has been increasing worldwide. The occurrence of HUA was upper in T2DM patients [24]. There were several differences in laboratory results between the diabetes and the non-diabetes with COVID-19.…”

Section: Discussionmentioning

confidence: 85%

A Study of Some Biochemical Parameters in COVID-19 Patients with Diabetes Mellitus: Comparative Study

Sattar

Al-Rayahi

2022

View full text Add to dashboard Cite

COVID-l9 is considered a global health emergency, this disease affects all individuals and its symptoms are similar to the common cold. The purpose of this study is to compare diabetic and non-diabetic patients in some biochemical tests of patients infected with COVID-l9. Of the l20 patients included in the study, 7l patients were males (59.l7%) and 49 were females (40.83%). The study showed that the highest percentage was in males with diabetes (63.33%), followed by non-diabetics (55.00%), without significant difference. As for the age group, most patients were over 50 years, and it was most common among non-diabetics in addition to diabetes. Mean glucose was significantly different between the diabetic group and the non-diabetic group. For the diabetic group, the mean blood sugar was 229.22 ± 82.25mg/dl, while the mean blood sugar in the non-diabetic group was l32.25 ± 44.08 mg/dl. In addition, there was a significant difference in mean HbA1c between the diabetic and non-diabetic groups p < .001. For the diabetic group, the mean HbA1c was 7.5l ± l.27 %, but in the non-diabetic group, the mean HbA1c was 5.41 ± 0.73%. While there was a significant difference between the two groups with and without diabetes in the mean ferritin ratio p < .00l. For the diabetic group, the mean serum ferritin was 638.78 ± 327.78 ng/ml, although in the non-diabetic group, the mean serum ferritin was 393.74 ± 330.83 ng/ml. There were no significant differences between the diabetic and non-diabetic group in the mean of D-dimer, urea, creatinine and uric acid, in the diabetic groups, the mean was 6.00 ± 5.80 ug/ml, 86.02 ± 64.27 mg/dl, 1.64+1.45mg/dl and 5.37 ± 3.11mg/dl, respectively. While in the non-diabetic group, the mean was 5.82 ± 5.76 ug/ml, 74.68 ± 68.27mg/dl, 1.88 ± 2.62 mg/dl, and 4.86 ± 2.62 mg/dl, respectively.

show abstract

<p>Study on the Risk Factors for Hyperuricaemia and Related Vascular Complications in Patients with Type 2 Diabetes Mellitus</p>

Cited by 9 publications

References 63 publications

Clinical significance of vascular endothelial growth factor and endothelin-1 in serum levels as novel indicators for predicting the progression of diabetic nephropathy

Clinical significance of vascular endothelial growth factor and endothelin-1 in serum levels as novel indicators for predicting the progression of diabetic nephropathy

Sodium-Glucose Cotransporter-2 (SGLT-2) Attenuates Serum Uric Acid (SUA) Level in Patients with Type 2 Diabetes

A Study of Some Biochemical Parameters in COVID-19 Patients with Diabetes Mellitus: Comparative Study

Contact Info

Product

Resources

About